2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon

Pfizer is transitioning from its COVID-era windfall into a diversified, non‑COVID growth strategy — bolstered by the $43bn Seagen buy and an up-to-$10bn Metsera deal for obesity assets — while reporting roughly $45bn in revenue for the first nine months of 2025, GAAP net income up 24% to $9.4bn, a $7.2bn cost‑savings target through 2027, and more than $7bn paid in dividends (348 consecutive quarterly payments), leaving it positioned as a lower‑risk, high‑income play amid looming patent expirations. Viking Therapeutics is a higher‑risk, clinical‑stage exposure to the fast‑growing obesity/diabetes market: lead candidate VK2735 (dual GLP‑1/GIP) is in phase 3 (injectable plus an oral formulation) after a phase‑2 signal of up to 14.7% mean weight loss at 13 weeks, and the company has >$715m in cash to fund pivotal trials while advancing other programs (VK2809, VK0214). Together, the pieces present a contrast between Pfizer’s de‑risked, dividend‑driven pivot into oncology and metabolic medicines and Viking’s speculative, potentially high‑upside bet on next‑generation weight‑loss therapeutics contingent on phase‑3 success.

Analysis

Pfizer is executing a deliberate pivot away from its COVID-era revenue concentration, reporting roughly $45 billion in revenue in the first nine months of 2025 and a 24% year‑over‑year increase in GAAP net income to $9.4 billion while paying more than $7 billion in dividends over the same period; the company has a long dividend record (348 consecutive quarterly payments) and a current yield near 7% amid share pressure. Management is de‑risking future growth via acquisitions and portfolio diversification: the $43 billion Seagen deal added four approved oncology drugs (Adcetris, Padcev, Tivdak, Tukysa), and the up‑to‑$10 billion Metsera transaction brings obesity GLP‑1 assets including a once‑monthly candidate, supported by a $7.2 billion net cost‑savings target through 2027. Viking Therapeutics is a high‑beta, clinical‑stage exposure: lead candidate VK2735 (dual GLP‑1/GIP) is in phase 3 with both injectable and oral programs after a phase 2 VENTURE signal of up to 14.7% mean weight loss at 13 weeks, and the company finished Q3 2025 with over $715 million in cash which management says funds phase 3 completion. Key risks differ by name: Pfizer faces patent cliffs (Eliquis, Ibrance) and integration/execution risk on M&A and cost saves, while Viking’s valuation is binary and hinges on phase‑3/regulatory outcomes and longer‑term efficacy versus established 68–72 week competitors.

Key Decisions for Investors

• Consider accumulating Pfizer selectively for income and pipeline exposure given a near‑7% yield and improving GAAP profits, but size positions conservatively and monitor execution on the $7.2 billion cost‑savings plan and integration of Metsera and Seagen
• Watch Pfizer near‑term catalysts (Metsera deal updates, commercialization traction for recent launches, quarterly results) and treat any positive operational beat or clear pipeline milestones as reweighting opportunities
• For risk‑tolerant investors, allocate a small, staged speculative position to Viking ahead of phase‑3 readouts, limit exposure to a size consistent with binary trial risk, and add on favorable interim data
• Monitor Viking-specific catalysts closely (phase‑3 endpoints, oral formulation tolerability, 68–72 week comparative durability) and retain flexibility to exit on negative pivotal signals despite current cash runway
• Use hedges (options or cash buffers) for larger Pfizer positions to protect dividend income against adverse patent or pipeline setbacks, and avoid concentrated exposure to Viking until regulatory risk is resolved